Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893346 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01893346 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 35 participants.
The verdict
NCT01893346, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
To assess the pharmacokinetics, safety and tolerability of a single dose of CAZ-AVI in children from 3 months of age to \<18 years.
Interventions
- DRUG CAZ-AVI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01893346
The ClinicalTrials.gov registry entry for NCT01893346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAZ-AVI is the first listed.
NCT01893346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01893346 about?
NCT01893346 is a clinical study titled "Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections". To assess the pharmacokinetics, safety and tolerability of a single dose of CAZ-AVI in children from 3 months of age to \<18 years.
What is the current status of trial NCT01893346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2013-07. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01893346?
The interventions under investigation include: CAZ-AVI (DRUG).
Who is sponsoring clinical trial NCT01893346?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.